| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC66479 | WAY-661957 Featured | Androgen Receptor modulator |
|
| DC66480 | XL413 Featured | XL413 is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC50 of 3.4 nM, and also shows potent effect with IC50s of 215, 42 nM on CK2, PIM1, respectively, and an EC50 of 118 nM on pMCM. |
|
| DC66481 | 6'-Bromo-8'-methyl-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'(2'H)-dione Featured |
|
|
| DC66482 | CK2α-IN-1 Featured | CK2α-IN-1 (compound 2) is a selective CK2α inhibitor (IC50=7.0 µM; Ki=1.6 µM) that exhibits a non-ATP-competitive mode of action. CK2α-IN-1 exhibits good potential for anticancer studies. |
|
| DC66483 | 2,3-Bis(2,6-diisopropylphenylimino)butane Featured |
|
|
| DC66484 | 2',4'-Dihydroxy-2-benzoylbenzoic Acid Featured |
|
|
| DC66485 | 1,8-Bis(tetramethylguanidino)naphthalene Featured |
|
|
| DC66486 | MCLA hydrochloride Featured | MCLA hydrochloride is a chemiluminescent reagent which can be used to quantify aqueous concentrations of superoxide. |
|
| DC66487 | GSK-3β inhibitor 12 Featured | GSK-3β inhibitor 12 (compound 15) is an inhibitor of GSK-3β. GSK-3β inhibitor 12 inhibits 49.11% and 37.11% activity of 25 μM and 50 μM GSK-3β, respectively. GSK-3β inhibitor 12 can be used for the research of neurodegenerative diseases. |
|
| DC66488 | CLK1-IN-4 Featured | CLK1-IN-4 (Compound 79) is an inhibitor for CDC like kinase 1 (CLK-1) with IC50 of 1.5-2 μM. |
|
| DC66489 | CB1 agonist 1 Featured | CB1 agonist 1 (compound 22) is an agonist of CB1. CB1 agonist 1 shows affinity to CB1 receptor with an pIC50 value of 5.7. CB1 agonist 1 can be used for the research of brain disorders. |
|
| DC66490 | CK2-IN-4 Featured | CK2-IN-4 (compound 5) is a protein kinase (CK2) inhibitor (IC50=8.6 µM). CK2-IN-4 has good potential for research in the areas of cancer, viral infections and glomerulonephritis. |
|
| DC66491 | BCR-ABL-IN-7 Featured |
|
|
| DC66492 | Tyrosine kinase-IN-7 Featured | Tyrosine kinase-IN-7 (compound 13h) is an inhibitor of the tyrosine kinase EGFR. The IC50s for inhibiting EGFR(WT) and EGFR(T790M) are 0.630 μM and 0.956 μM respectively. Tyrosine kinase-IN-7 has antitumor activity against four cancer cell lines (HepG2, HCT-116, MCF-7, and A431) with IC50s of 13.02 μM, 10.14 μM, 12.68 μM, and 47.05 μM, respectively. |
|
| DC66493 | JY-2 Featured | JY-2 is a moderately selective and orally active Forkhead transcription factor forkhead box O1 (FoxO1) inhibitor that inhibits FoxO1 transcriptional activity with an IC50 of 22 μM. JY-2 shows moderate inhibition against FoxO3a and FoxO4. JY-2 shows anti-diabetic activity. |
|
| DC66494 | Casein kinase 1δ-IN-14 Featured | Casein kinase 1δ-IN-14 (compound 481) is a casein kinase inhibitor that can be used to study neurodegenerative diseases such as Alzheimer's disease. |
|
| DC66495 | ROS kinases-IN-2 Featured | ROS kinases-IN-2 is a ROS kinase inhibitor with 21.53% inhibition at 10 μM. |
|
| DC66496 | HIF-PHD-IN-3 Featured | HIF-PHD-IN-3 (compound 4) is a potent hiPSC-CM cardioprotective scaffold. HIF-PHD-IN-3 can induce upregulation of heme oxygenase-1. |
|
| DC66497 | Clevidipine Impurity 39 Featured |
|
|
| DC66498 | 5-Phenyl-1H-indole Featured |
|
|
| DC66499 | 4-Isopropylbenzoyl chloride Featured |
|
|
| DC66500 | OTUB2-IN-1 Featured | OTUB2-IN-1, a specific inhibitor of OTUB2 (KD: ~12 μM), reduces PD-L1 protein expression in tumor cells and inhibits tumor growth by promoting robust intra-tumor infiltration of cytotoxic T lymphocytes (CTL) . |
|
| DC66501 | N-Acetylcysteine amide Featured | N-Acetylcysteine amide is a cell membranes and blood brain barrier permeant thiol antioxidant and neuroprotective agent, reduces ROS production. |
|
| DC66502 | Ethyl 2-(4-hydroxyphenyl)-2-oxoacetate Featured |
|
|
| DC66503 | Boc-DL-leucine Featured |
|
|
| DC66504 | N-Boc-3-Iodo-L-alanine benzyl ester Featured |
|
|
| DC66505 | trans-Glutaconic acid Featured |
|
|
| DC66506 | Naphthalene, 2-phenyl- Featured |
|
|
| DC66507 | (1H-benzodimidazol-2-yl)methanamine hydrochloride Featured |
|
|
| DC26111 | Cevidoplenib Featured | Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC50s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively. |
|
